ArticleCancer immunology, immunotherapy : CII2024

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients.

A Gawaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.